Aquestive Therapeutics (AQST) Stock Forecast, Price Target & Predictions
AQST Stock Forecast
Aquestive Therapeutics stock forecast is as follows: an average price target of $10.00 (represents a 173.97% upside from AQST’s last price of $3.65) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
AQST Price Target
The average price target for Aquestive Therapeutics (AQST) is $10.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 173.97% upside from AQST's last price of $3.65.
AQST Analyst Ratings
According to 6 Wall Street analysts, Aquestive Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AQST stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aquestive Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 06, 2024 | Thomas Flaten | Loop Capital Markets | $10.00 | $4.79 | 108.82% | 173.97% |
| Jun 25, 2024 | Thomas Flaten | Loop Capital Markets | $7.00 | $2.31 | 203.03% | 91.78% |
| Apr 11, 2024 | David Amsellem | Piper Sandler | $10.00 | $4.07 | 145.70% | 173.97% |
| Mar 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $9.00 | $5.51 | 63.34% | 146.58% |
| Mar 15, 2024 | Francois Brisebois | Oppenheimer | $12.00 | $6.09 | 97.04% | 228.77% |
The latest Aquestive Therapeutics stock forecast, released on Nov 06, 2024 by Thomas Flaten from Loop Capital Markets, set a price target of $10.00, which represents a 108.82% increase from the stock price at the time of the forecast ($4.79), and a 173.97% increase from AQST last price ($3.65).
Aquestive Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $10.00 | $9.60 |
| Last Closing Price | $3.65 | $3.65 | $3.65 |
| Upside/Downside | -100.00% | 173.97% | 163.01% |
In the current month, the average price target of Aquestive Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aquestive Therapeutics's last price of $3.65. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 17, 2024 | Cantor Fitzgerald | Overweight | Initialise | |
| Dec 02, 2024 | Lake Street | Buy | Buy | Hold |
| Sep 30, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 25, 2024 | Lake Street | Buy | Buy | Hold |
| May 09, 2024 | Alliance Global Partners | Buy | Buy | Hold |
| Mar 09, 2023 | Wedbush | Outperform | Upgrade |
Aquestive Therapeutics's last stock rating was published by Cantor Fitzgerald on Dec 17, 2024. The company Initialise its AQST rating from "null" to "Overweight".
Aquestive Therapeutics Financial Forecast
Aquestive Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.00M | $13.24M | $11.13M | $10.68M | $11.46M | $13.27M | $12.27M | $11.08M | $13.29M | $15.35M | $11.12M | $7.15M | $8.26M | $21.68M | $8.77M | $16.42M | $12.42M | $11.13M | $12.64M | $13.27M |
| Avg Forecast | $15.22M | $13.66M | $13.06M | $13.08M | $13.09M | $12.69M | $12.39M | $12.26M | $11.66M | $11.51M | $11.01M | $9.94M | $10.42M | $11.00M | $10.57M | $10.13M | $9.36M | $11.01M | $9.48M | $8.97M | $6.26M | $8.72M | $8.77M | $10.07M | $15.84M | $9.97M | $9.19M | $11.59M | $8.91M |
| High Forecast | $16.96M | $15.22M | $14.55M | $14.08M | $15.12M | $12.72M | $12.42M | $13.66M | $12.36M | $11.51M | $12.27M | $11.07M | $11.61M | $11.00M | $10.57M | $10.13M | $9.36M | $11.01M | $9.48M | $8.97M | $6.26M | $8.72M | $8.77M | $10.07M | $15.84M | $9.97M | $9.19M | $11.59M | $10.70M |
| Low Forecast | $13.94M | $12.51M | $11.96M | $12.28M | $12.12M | $12.65M | $12.36M | $11.23M | $10.88M | $11.51M | $10.09M | $9.10M | $9.54M | $11.00M | $10.57M | $10.13M | $9.36M | $11.01M | $9.48M | $8.97M | $6.26M | $8.72M | $8.77M | $10.07M | $15.84M | $9.97M | $9.19M | $11.59M | $7.13M |
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.13% | 1.20% | 1.12% | 1.03% | 1.04% | 1.25% | 1.21% | 1.18% | 1.21% | 1.62% | 1.24% | 1.14% | 0.95% | 2.47% | 0.87% | 1.04% | 1.25% | 1.21% | 1.09% | 1.49% |
Aquestive Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $11.66M, with a low forecast of $10.88M, and a high forecast of $12.36M. AQST's average Quarter revenue forecast represents a -10.32% decrease compared to the company's last Quarter revenue of $13.00M (Sep 23).
Aquestive Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-2.38M | $-4.21M | $9.91M | $-10.65M | $-8.25M | $-12.06M | $-9.01M | $-30.69M | $-7.23M | $-5.40M | $-7.77M | $-14.54M | $-13.12M | $1.21M | $-12.87M | $-9.11M | $-15.05M | $-17.81M | $-12.05M | $-12.36M |
| Avg Forecast | $-10.80M | $-9.69M | $-9.27M | $-9.28M | $-9.29M | $-9.00M | $-8.79M | $-8.70M | $-8.27M | $-8.17M | $-7.82M | $-7.05M | $-7.39M | $-8.24M | $-7.92M | $-10.99M | $-7.01M | $-8.24M | $-7.09M | $-8.13M | $-4.69M | $-6.53M | $-6.56M | $-12.32M | $-11.86M | $-7.47M | $-6.88M | $-9.88M | $-6.96M |
| High Forecast | $-9.89M | $-8.88M | $-8.49M | $-8.72M | $-8.60M | $-8.98M | $-8.77M | $-7.97M | $-7.72M | $-8.17M | $-7.16M | $-6.46M | $-6.77M | $-8.24M | $-7.92M | $-8.79M | $-7.01M | $-8.24M | $-7.09M | $-6.51M | $-4.69M | $-6.53M | $-6.56M | $-9.86M | $-11.86M | $-7.47M | $-6.88M | $-7.91M | $-5.56M |
| Low Forecast | $-12.04M | $-10.80M | $-10.33M | $-9.99M | $-10.73M | $-9.03M | $-8.81M | $-9.70M | $-8.77M | $-8.17M | $-8.71M | $-7.86M | $-8.24M | $-8.24M | $-7.92M | $-13.19M | $-7.01M | $-8.24M | $-7.09M | $-9.76M | $-4.69M | $-6.53M | $-6.56M | $-14.79M | $-11.86M | $-7.47M | $-6.88M | $-11.86M | $-8.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.29% | 0.54% | -1.40% | 1.44% | 1.00% | 1.52% | 0.82% | 4.38% | 0.88% | 0.76% | 0.96% | 3.10% | 2.01% | -0.18% | 1.04% | 0.77% | 2.02% | 2.59% | 1.22% | 1.78% |
2 analysts predict AQST's average Quarter EBITDA for Jun 23 to be $-7.82M, with a high of $-7.16M and a low of $-8.71M. This is -178.88% lower than Aquestive Therapeutics's previous annual EBITDA (Mar 23) of $9.91M.
Aquestive Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $-2.04M | $-5.79M | $19.31M | $-18.15M | $-16.22M | $-19.84M | $-16.70M | $-47.97M | $-14.55M | $-12.37M | $-14.67M | $-20.37M | $-16.55M | $-2.33M | $-16.53M | $-12.64M | $-18.41M | $-20.47M | $-14.73M | $-15.04M |
| Avg Forecast | $-11.84M | $-11.84M | $-12.20M | $-12.02M | $-12.18M | $-10.70M | $-10.47M | $-8.08M | $-7.74M | $-10.32M | $-10.63M | $-12.75M | $-20.56M | $-26.23M | $-32.55M | $-16.12M | $-42.36M | $-39.82M | $-39.70M | $-15.35M | $-45.82M | $-41.52M | $-40.30M | $-15.83M | $-35.00M | $-65.00M | $-57.58M | $-12.08M | $-8.46M |
| High Forecast | $-10.55M | $-10.55M | $-10.87M | $-10.31M | $-11.31M | $-9.53M | $-9.33M | $-7.20M | $-3.87M | $-9.19M | $-9.46M | $-11.36M | $-18.31M | $-26.23M | $-32.55M | $-12.90M | $-42.36M | $-39.82M | $-39.70M | $-12.28M | $-45.82M | $-41.52M | $-40.30M | $-12.66M | $-35.00M | $-65.00M | $-57.58M | $-9.66M | $-6.77M |
| Low Forecast | $-13.60M | $-13.60M | $-14.02M | $-13.74M | $-13.05M | $-12.29M | $-12.03M | $-9.28M | $-10.64M | $-11.86M | $-12.21M | $-14.65M | $-23.61M | $-26.23M | $-32.55M | $-19.35M | $-42.36M | $-39.82M | $-39.70M | $-18.43M | $-45.82M | $-41.52M | $-40.30M | $-18.99M | $-35.00M | $-65.00M | $-57.58M | $-14.49M | $-10.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.20% | 0.55% | -1.51% | 0.88% | 0.62% | 0.61% | 1.04% | 1.13% | 0.37% | 0.31% | 0.96% | 0.44% | 0.40% | 0.06% | 1.04% | 0.36% | 0.28% | 0.36% | 1.22% | 1.78% |
Aquestive Therapeutics's average Quarter net income forecast for Jun 23 is $-10.63M, with a range of $-12.21M to $-9.46M. AQST's average Quarter net income forecast represents a -155.04% decrease compared to the company's last Quarter net income of $19.31M (Mar 23).
Aquestive Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.38M | $7.36M | $7.46M | $11.81M | $12.46M | $15.59M | $13.02M | $14.98M | $12.13M | $13.13M | $13.23M | $15.58M | $11.80M | $13.89M | $14.61M | $16.47M | $13.71M | $16.25M | $17.91M | $12.35M |
| Avg Forecast | $15.92M | $14.29M | $13.66M | $13.68M | $13.69M | $13.27M | $12.96M | $12.83M | $12.20M | $12.04M | $11.52M | $10.40M | $10.90M | $11.51M | $11.06M | $10.60M | $9.79M | $11.52M | $9.91M | $9.39M | $6.55M | $9.13M | $9.17M | $10.54M | $16.57M | $10.43M | $9.61M | $12.12M | $6.95M |
| High Forecast | $17.74M | $15.92M | $15.22M | $14.73M | $15.82M | $13.31M | $12.99M | $14.29M | $12.93M | $12.05M | $12.84M | $11.58M | $12.14M | $11.51M | $11.06M | $10.60M | $9.79M | $11.52M | $9.91M | $9.39M | $6.55M | $9.13M | $9.17M | $10.54M | $16.57M | $10.43M | $9.61M | $12.12M | $8.34M |
| Low Forecast | $14.58M | $13.09M | $12.51M | $12.85M | $12.68M | $13.24M | $12.93M | $11.75M | $11.38M | $12.04M | $10.55M | $9.52M | $9.98M | $11.51M | $11.06M | $10.60M | $9.79M | $11.52M | $9.91M | $9.39M | $6.55M | $9.13M | $9.17M | $10.54M | $16.57M | $10.43M | $9.61M | $12.12M | $5.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.61% | 0.64% | 0.72% | 1.08% | 1.08% | 1.41% | 1.23% | 1.53% | 1.05% | 1.32% | 1.41% | 2.38% | 1.29% | 1.52% | 1.39% | 0.99% | 1.31% | 1.69% | 1.48% | 1.78% |
Aquestive Therapeutics's average Quarter SG&A projection for Dec 23 is $12.20M, based on 4 Wall Street analysts, with a range of $11.38M to $12.93M. The forecast indicates a 65.17% rise compared to AQST last annual SG&A of $7.38M (Sep 23).
Aquestive Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 6 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.00 | $0.35 | $-0.37 | $-0.30 | $-0.44 | $-0.40 | $-1.19 | $-0.37 | $-0.33 | $-0.41 | $-0.60 | $-0.49 | $-0.07 | $-0.49 | $-0.48 | $-0.74 | $-0.82 | $-0.59 | $-0.64 |
| Avg Forecast | $-0.13 | $-0.13 | $-0.13 | $-0.13 | $-0.13 | $-0.12 | $-0.12 | $-0.09 | $-0.09 | $-0.11 | $-0.12 | $-0.14 | $-0.23 | $-0.29 | $-0.36 | $-0.42 | $-0.47 | $-0.44 | $-0.44 | $-0.42 | $-0.50 | $-0.46 | $-0.44 | $-0.47 | $-0.39 | $-0.71 | $-0.63 | $-0.52 | $-0.24 |
| High Forecast | $-0.12 | $-0.12 | $-0.12 | $-0.11 | $-0.12 | $-0.10 | $-0.10 | $-0.08 | $-0.04 | $-0.10 | $-0.10 | $-0.12 | $-0.20 | $-0.29 | $-0.36 | $-0.42 | $-0.47 | $-0.44 | $-0.44 | $-0.42 | $-0.50 | $-0.46 | $-0.44 | $-0.47 | $-0.39 | $-0.71 | $-0.63 | $-0.52 | $-0.19 |
| Low Forecast | $-0.15 | $-0.15 | $-0.15 | $-0.15 | $-0.14 | $-0.13 | $-0.13 | $-0.10 | $-0.12 | $-0.13 | $-0.13 | $-0.16 | $-0.26 | $-0.29 | $-0.36 | $-0.42 | $-0.47 | $-0.44 | $-0.44 | $-0.42 | $-0.50 | $-0.46 | $-0.44 | $-0.47 | $-0.39 | $-0.71 | $-0.63 | $-0.52 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.00% | -2.50% | 1.64% | 1.04% | 1.23% | 0.95% | 2.55% | 0.84% | 0.76% | 0.96% | 1.19% | 1.07% | 0.16% | 1.05% | 1.25% | 1.03% | 1.29% | 1.15% | 2.67% |
According to 2 Wall Street analysts, Aquestive Therapeutics's projected average Quarter EPS for Jun 23 is $-0.12, with a low estimate of $-0.13 and a high estimate of $-0.10. This represents a -133.33% decrease compared to AQST previous annual EPS of $0.35 (Mar 23).
Aquestive Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EVOK | Evoke Pharma | $4.59 | $18.00 | 292.16% | Buy |
| AQST | Aquestive Therapeutics | $3.85 | $10.00 | 159.74% | Buy |
| IRWD | Ironwood Pharmaceuticals | $3.53 | $8.50 | 140.79% | Buy |
| DVAX | Dynavax | $12.90 | $29.00 | 124.81% | Buy |
| LNTH | Lantheus | $92.66 | $155.00 | 67.28% | Buy |
| AMPH | Amphastar Pharmaceuticals | $40.85 | $66.00 | 61.57% | Buy |
| ANIP | ANI Pharmaceuticals | $55.83 | $79.00 | 41.50% | Buy |
| ORGO | Organogenesis | $3.57 | $5.00 | 40.06% | Buy |
| ALKS | Alkermes | $30.75 | $37.50 | 21.95% | Hold |
| LFCR | Lifecore Biomedical | $7.47 | $6.50 | -12.99% | Buy |